By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cytokinetics, Inc. 

280 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-624-3000 Fax: 650-624-3010


SEARCH JOBS



Segment
Drug Discovery





Company News
Cytokinetics (CYTK) Announces Dosing Of First Patient In Japan In GALACTIC-HF, Phase III Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure 9/19/2017 7:35:32 AM
Cytokinetics (CYTK) Announces Presentation Of Additional Results From COSMIC-HF At The HFSA 21st Annual Scientific Meeting 9/18/2017 8:14:26 AM
Cytokinetics (CYTK) Announces Additional Results From COSMIC-HF To Be Presented At The HFSA 21st Annual Scientific Meeting 9/12/2017 8:29:44 AM
Cytokinetics (CYTK) Reports Second Quarter 2017 Financial Results 8/3/2017 1:47:15 PM
Cytokinetics (CYTK) Announces Positive Results From Phase II Clinical Trial Of Omecamtiv Mecarbil In Japanese Patients With Heart Failure 8/2/2017 10:25:19 AM
Cytokinetics (CYTK) To Announce Second Quarter Results On August 2, 2017 7/27/2017 12:55:42 PM
Cytokinetics (CYTK) Announces Start Of FORTITUDE-ALS, A Phase II Clinical Trial Of CK-2127107 In Patients With Amyotrophic Lateral Sclerosis 7/27/2017 11:38:51 AM
Cytokinetics (CYTK) Announces Baseline Data From First Cohort Of Phase II Clinical Trial Of CK-2127107 In Patients With SMA 7/5/2017 9:03:24 AM
Cytokinetics (CYTK) Announces Orphan Drug Designation For CK-2127107 For The Treatment Of Spinal Muscular Atrophy 5/15/2017 7:10:49 AM
Cytokinetics (CYTK) To Hold Annual Meeting Of Stockholders 5/12/2017 7:45:45 AM
12345678910...
//-->